Literature DB >> 2515047

Development of human liver UDP-glucuronosyltransferases.

B Burchell1, M Coughtrie, M Jackson, D Harding, S Fournel-Gigleux, J Leakey, R Hume.   

Abstract

The development of multiple UDPGT activities towards eight substrates has been studied in fetal term and adult post-mortem (less than 5 h after death) liver samples. Most fetal and term liver activities were less than 14% of adult values, except that towards 5-hydroxytryptamine which was present in fetal and term liver at adult levels. The majority of UDPGT activities develop to adult levels within 10-20 weeks postnatally, and even premature (30 weeks) which survive for up to 10 weeks will develop these enzyme activities. Immunoblot analysis of human liver microsomes and cDNA cloning of human UDPGT shows the existence of the family of isoenzymes in man, and it is important to determine the developmental pattern of individual drug glucuronidating enzymes in liver. Immunoblot analysis of developing liver shows the presence of two major UDPGT polypeptides in fetal liver, whereas more than five are observed in adult liver. The investigation of substrate specificity of individual UDPGTs by expression of cloned genes in COS-7 cells and the use of antibodies will facilitate the identification of enzymes present in perinatal liver.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2515047     DOI: 10.1159/000457587

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  28 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Uridine 5'-diphosphoglucuronic acid (UDPGLcUA) in the human fetal liver, kidney and placenta.

Authors:  M Cappiello; L Giuliani; A Rane; G M Pacifici
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

3.  Genetic variation, expression and ontogeny of sulfotransferase SULT2A1 in humans.

Authors:  L Ekström; A Rane
Journal:  Pharmacogenomics J       Date:  2015-03-24       Impact factor: 3.550

4.  Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population.

Authors:  Ya-Li Nie; Hang He; Jiang-Feng Li; Xiang-Guang Meng; Liang Yan; Pei Wang; Shu-Jie Wang; Hong-Zheng Bi; Li-Rong Zhang; Quan-Cheng Kan
Journal:  Eur J Clin Pharmacol       Date:  2016-10-05       Impact factor: 2.953

5.  NRF2-Independent Regulation of Intestinal Constitutive Androstane Receptor by the Pro-Oxidants Cadmium and Isothiocyanate in hUGT1 Mice.

Authors:  Miles Paszek; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2019-11-08       Impact factor: 3.922

6.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

7.  Induction of bilirubin clearance by the constitutive androstane receptor (CAR).

Authors:  Wendong Huang; Jun Zhang; Steven S Chua; Mohammed Qatanani; Yunqing Han; Riccarda Granata; David D Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

8.  Sulphation and glucuronidation of ritodrine in human foetal and adult tissues.

Authors:  G M Pacifici; M Kubrich; L Giuliani; M de Vries; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants.

Authors:  Antonia M Calafat; Jennifer Weuve; Xiaoyun Ye; Lily T Jia; Howard Hu; Steven Ringer; Ken Huttner; Russ Hauser
Journal:  Environ Health Perspect       Date:  2008-12-10       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.